相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Elective Switching from Infliximab to Adalimumab in Stable Crohn's Disease
Frank Hoentjen et al.
INFLAMMATORY BOWEL DISEASES (2013)
Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease
P. S. A. de Silva et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Anti-TNF antibody therapy in Crohn's disease: the risk of a switch
Elena Ricart et al.
GUT (2012)
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
Gert Van Assche et al.
GUT (2012)
SWITCHing anti-TNF for nonclinical reasons? Think again!
Garret Cullen
INFLAMMATORY BOWEL DISEASES (2012)
Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2012)
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
Lior Katz et al.
INFLAMMATORY BOWEL DISEASES (2012)
Long-term durability of response to adalimumab in Crohn's disease
M. Chaparro et al.
INFLAMMATORY BOWEL DISEASES (2012)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register
E. Lie et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)
Liisa M. Virkki et al.
CLINICAL RHEUMATOLOGY (2011)
Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: 26-week Data of the FACTS II Survey
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2011)
Efficacy in current practice of switching between anti-tumour necrosis factor-α agents in spondyloarthropathies
Julien Paccou et al.
RHEUMATOLOGY (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders
D. Laharie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)
G. T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience
A. Oussalah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
G. G. Kaplan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study
L. Peyrin-Biroulet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial
J. Hinojosa et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
WJ Sandborn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
